Coronary Heart Disease
Conditions
Interventions
Experimental group:PCSK9 inhibitors combined with standard drug therapy
Sponsors
the First Affiliated Hospital of Guangxi Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. At least 18 years old; 2. CAG shows significant narrowing in at least one coronary artery + treatment with drug-eluting stent implantation.
Exclusion criteria
Exclusion criteria: 1.Used anti-inflammatory medications for six months prior to the implantation of the stent, accompanied by inflammatory diseases such as severe infections and autoimmune diseases. 2. Implanted with a metal bare stent or a biodegradable stent. 3. Unable to tolerate oral antiplatelet medications, did not regularly take antiplatelet drugs post-surgery, or has a special medication history. 4. Diseases causing immune dysfunction or other serious systemic diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Target Lesion Failure; | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of Life Rating;Safety and tolerability; | — |
Countries
China
Contacts
Public ContactYubo Xie
Department of Anesthesiology, the First Affiliated Hospital of Guangxi Medical University
Outcome results
None listed